Completes successful Analytical Validation study and initiates CLIA Validation study
On track for commercial availability of DetermaVu™ in 2H 2019
Conference Call Today at 4:30 PM EDT
ALAMEDA, Calif., May 14, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of lung cancer, today reported financial and operating results for the first quarter ended March 31, 2019 and provided a corporate update.
“During the first quarter and now into the second quarter, we continued to make great strides advancing DetermaVu™ through clinical development,” commented William Annett, President and Chief Executive Officer of OncoCyte. “In addition to the previously-reported positive results of our R&D Validation study, we recently announced positive results from our Analytical Validation study of DetermaVu™. We have moved quickly into the next phase and expect to complete CLIA Laboratory Validation soon. We will then proceed to the final study before commercialization, an approximately 440 patient blinded prospective Clinical Validation study.”
“With each successful validation step, we are rapidly approaching commercial availability, which we anticipate in the second half of this year. In parallel, we have begun to develop plans to explore the utility of DetermaVu™ in other solid tumor cancer indications with the goal of making this novel technology available to as many patients as possible. We continue to believe that DetermaVu™, which leverages our proprietary Immune System Interrogation approach to detect subtle changes in immune biomarkers in response to early-stage cancer, is poised to change the paradigm in lung cancer diagnostics. We look forward to efficiently completing the remaining development steps and transitioning to a commercial-stage company.”
- Successfully completed Analytical Validation and initiated CLIA Laboratory Validation study
- Announced a late-breaking abstract and discussion session at the American Thoracic Society 2019 International Conference detailing the compelling results from the R&D Validation study, a blinded, prospective study demonstrating best-in-class performance with sensitivity of 90% and specificity of 75%
- Completed a successful equity raise of $37.3 million in net proceeds which provides the funding to complete the development of DetermaVu™ and initiate commercialization efforts.
- On-track to complete remaining validation studies by mid-year and make DetermaVu™ commercially available in the second half of 2019
Remaining Validation Pathway for DetermaVu™:
- 2Q 2019: CLIA Laboratory Validation study – Currently underway to rerun between 100 and 120 patient blood samples previously run in the R&D Validation study to confirm that the same positive results are obtained on the analytically validated systems in OncoCyte’s CLIA laboratory
- Mid-year 2019: Clinical Validation study – Will run approximately 440 blinded, prospectively-collected blood samples to establish DetermaVu™’s performance in an independent, blinded data set as a final confirmation of test sensitivity and specificity in OncoCyte’s CLIA lab setting
- 2H 2019: Anticipated commercial availability of DetermaVu™
- Post-launch (2020 initiation): Clinical Utility study – Will conduct a real world evidence study to demonstrate a net improvement in patient outcomes and cost savings for the healthcare system from the use of DetermaVu™ as a confirmatory diagnostic test for lung cancer
First Quarter 2019 Financial Highlights
At March 31, 2019, OncoCyte had cash, cash equivalents and marketable securities of $39.9 million as compared to $8.4 million at December 31, 2018. The balance sheet was strengthened in February 2019 with the successful equity raise of $37.3 million in net proceeds from an underwritten public offering.
For the first quarter ended March 31, 2019, OncoCyte incurred a net loss of $3.9 million, or $(0.08) per share, as compared to $3.8 million, or $(0.12) per share, for the three months ended March 31, 2018.
Operating expenses for the three months ended March 31, 2019 were $4.0 million, and $3.2 million on an as-adjusted basis, as compared to $3.9 million, or $3.4 million on an as adjusted basis, for the same period in 2018.
The reconciliation between GAAP and non-GAAP operating expenses is provided in the financial tables included with this earnings release.
Research and development expenses for the quarter ended March 31, 2019 were $1.3 million as compared to $1.5 for the same period in 2018, relatively unchanged quarter over quarter, as OncoCyte continued to focus resources on the development and commercialization of DetermaVu™.
General and administrative expenses for the three months ended March 31, 2019 were $2.4 million, as compared to $1.7 million for the same period in 2018, an increase of $0.7 million. This increase is primarily attributable to $0.4 million in personnel and related expenses and $0.3 million in stock-based
compensation expense due to increased grants of equity awards.
Sales and marketing expenses for the three months ended March 31, 2019 were $0.2 million, as compared to $0.7 million for the same period in 2018, a decrease of $0.5 million, primarily attributable to a decrease in marketing personnel and consultants as OncoCyte concentrated its resources on the development of DetermaVu™ rather than on marketing related activities.
The Company will host a conference call today, May 14, 2019, at 4:30 pm EDT / 1:30 pm PDT to discuss the results along with recent corporate developments.
The dial-in number in the U.S./Canada is 877-407-9716; for international participants, the number is 201-493-6779. For all callers, please refer to Conference ID 13689785. To access the live webcast, go to the investor relations section on the Company’s website, http://investors.oncocyte.com/events-and-presentations.
DetermaVu™ is being developed as an intermediate step to confirm the absence of cancer between imaging modalities (LDCTs) detecting suspicious lung nodules and downstream invasive procedures that determine if the nodules are malignant. OncoCyte estimates that a $2 billion to $4.7 billion annual market could develop in the U.S. for its confirmatory lung cancer liquid biopsy test, depending on the scope of physician utilization, market penetration and reimbursable pricing.
DetermaVu™ has the potential to dramatically reduce U.S. healthcare costs by billions of dollars each year by eliminating unnecessary biopsies, which, according to a study of Medicare data by an independent health economics firm, cost on average $14,634 each. In addition, DetermaVu™ can provide great benefit to patients by avoiding invasive biopsies and the complications that arise in up to 24% of those procedures, and deaths that occur in up to 1% of cases.
DetermaVu™ is a trademark of OncoCyte Corporation.
About OncoCyte Corporation
OncoCyte is focused on the development and commercialization of novel, non-invasive blood (“liquid biopsy”) diagnostic tests for the early detection of lung cancer. Early detection of cancer can improve health outcomes, reduce the cost of care, and improve patients’ quality of life. Liquid biopsy diagnostic tests like those OncoCyte is developing may reduce the need for costlier and riskier diagnostic procedures such as invasive biopsy procedures. OncoCyte is focusing its efforts on the development of DetermaVu™ as a non-invasive confirmatory diagnostic test for lung cancer. DetermaVu™ is being developed using proprietary sets of genetic molecular markers that differentially express in lung cancer. OncoCyte also plans to conduct research to identify additional molecular markers, acquire or license markers and related technology, and develop cancer tests based on those markers.
OncoCyte Forward Looking Statements
Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) are forward-looking statements. These statements include those pertaining to the implementation and results of research, development, clinical trials and studies, commercialization plans, future financial and/or operating results, and future opportunities for OncoCyte, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of our third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, the need and ability to obtain future capital, and maintenance of intellectual property rights, and the need to obtain third party reimbursement for patients’ use of any diagnostic tests we commercialize. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly as such statements should be evaluated together with the many uncertainties that affect the business of OncoCyte, particularly those mentioned in the “Risk Factors” and other cautionary statements found in OncoCyte’s Securities and Exchange Commission filings. OncoCyte disclaims any intent or obligation to update these forward-looking statements, except as required by law.
LifeSci Advisors, LLC
|CONDENSED BALANCE SHEETS|
|March 31, 2019|
|(Unaudited)||December 31, 2018|
|Cash and cash equivalents||$||39,257||$||8,034|
|Marketable equity securities||606||428|
|Prepaid expenses and other current assets||1,130||180|
|Total current assets||40,993||8,642|
|Machinery and equipment, net||486||614|
|Deposits and other noncurrent assets||198||262|
|LIABILITIES AND SHAREHOLDERS' EQUITY|
|Amount due to BioTime and affiliates||$||-||$||2,101|
|Accrued expenses and other current liabilities||1,957||2,109|
|Loan payable, current||800||800|
|Financing lease liability, current||304||385|
|Total current liabilities||3,197||5,561|
|Loan payable, net of deferred financing costs, noncurrent||159||347|
|Financing lease liability, noncurrent||134||187|
|Preferred stock, no par value, 5,000 shares authorized; none issued and outstanding||-||-|
|Common stock, no par value, 85,000 shares authorized; 51,973 and 40,664 shares issued |
and outstanding at March 31, 2019 and December 31, 2018, respectively
|Accumulated other comprehensive loss||-||-|
|Total shareholders' equity||38,187||3,423|
|TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY||$||41,677||$||9,518|
|CONDENSED STATEMENTS OF OPERATIONS|
|(IN THOUSANDS, EXCEPT PER SHARE DATA)|
|Three Months Ended |
|Research and development||$||1,343||$||1,461|
|General and administrative||2,449||1,787|
|Sales and marketing||205||658|
|Total operating expenses||3,997||3,906|
|Loss from operations||(3,997||)||(3,906||)|
|OTHER INCOME (EXPENSES), NET|
|Interest expense, net||(19||)||(60||)|
|Unrealized gain on marketable equity securities||178||190|
|Other expenses, net||(26||)||(2||)|
|Total other income, net||133||128|
|Net loss per share: basic and diluted||$||(0.08||)||$||(0.12||)|
|Weighted average common shares outstanding: basic and diluted||46,647||31,676|
|CONDENSED STATEMENTS OF CASH FLOWS|
|Three Months Ended|
|CASH FLOWS FROM OPERATING ACTIVITIES:|
|Adjustments to reconcile net loss to net cash used in operating activities:|
|Amortization of intangible assets||-||61|
|Amortization of prepaid maintenance||9||-|
|Unrealized gain on marketable equity securities||(178||)||(190||)|
|Amortization of debt issuance costs||12||22|
|Changes in operating assets and liabilities:|
|Amount due to BioTime and affiliates||(2,101||)||7|
|Prepaid expenses and other current assets||(950||)||(324||)|
|Accounts payable and accrued liabilities||(468||)||999|
|Net cash used in operating activities||(6,718||)||(2,753||)|
|CASH FLOWS FROM INVESTING ACTIVITIES:|
|Purchase of equipment||(7||)||(5||)|
|Security deposit and other||54||-|
|Net cash provided by (used in) investing activities||47||(5||)|
|CASH FLOWS FROM FINANCING ACTIVITIES:|
|Proceeds from exercise of options||943||51|
|Proceeds from sale of common shares||40,250||8,000|
|Financing costs to issue common shares||(2,965||)||-|
|Repayment of loan payable||(200||)||(200||)|
|Repayment of financing lease obligations||(134||)||(81||)|
|Net cash provided by financing activities||37,894||7,770|
|NET INCREASE IN CASH AND CASH EQUIVALENTS||31,223||5,012|
|CASH AND CASH EQUIVALENTS:|
|At beginning of the period||8,034||7,600|
|At end of the period||$||39,257||$||12,612|
Non-GAAP Financial Measures
This earnings release includes operating expenses prepared in accordance with accounting principles generally accepted in the United States (GAAP), and includes certain historical non-GAAP operating expenses. In particular, OncoCyte has provided non-GAAP total operating expenses, adjusted to exclude noncash stock-based compensation and depreciation and amortization expense. Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable financial measures prepared in accordance with GAAP. However, OncoCyte believes the presentation of non-GAAP total operating expenses, when viewed in conjunction with our GAAP total operating expenses, is helpful in understanding OncoCyte’s ongoing operating expenses and its programs.
Furthermore, management uses these non-GAAP financial measures in the aggregate to establish budgets and operational goals, to manage OncoCyte’s business and to evaluate its performance and its programs.
Reconciliation of Non-GAAP Financial Measure
Adjusted Operating Expenses
|Amounts In Thousands|
|For the Three Months Ended |
March 31, 2019 (unaudited)
|GAAP Operating Expenses - as reported||$||3,997|
|Stock-based compensation expense||(686||)|
|Depreciation and amortization expense||(119||)|
|Non-GAAP Operating Expenses, as adjusted||$||3,192|